PP
CNCE

PDT Partners’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

PDT Partners’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-12,285
Closed -$61K – 995
2021
Q1 		$61K Buy
+12,285
New +$99.3K ﹤0.01% 753
2018
Q3 		– Sell
-16,500
Closed -$278K – 555
2018
Q2 		$278K Sell
16,500
-115,287
-87% -$2.24M 0.01% 448
2018
Q1 		$3.02M Sell
131,787
-11,916
-8% -$265K 0.1% 221
2017
Q4 		$3.72M Buy
143,703
+84,310
+142% +$1.7M 0.11% 227
2017
Q3 		$876K Buy
+59,393
New +$862K 0.03% 374

Other funds holding CNCE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

PDT Partners's CNCE Position: Q2 2021 in Review

PDT Partners sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2021, closing a stake of 12,285 shares — an estimated $61K sold.

PDT Partners first reported a position in CNCE in Q3 2017 and held it in 5 quarters. The position peaked at $3.72M in Q4 2017. 79 funds tracked by Wall St. Rank hold CNCE as of Q2 2021.

  • PDT Partners reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
  • PDT Partners sold 12,285 Concert Pharmaceuticals, Inc. shares in Q2 2021, an estimated $61K.
  • PDT Partners first reported a position in Concert Pharmaceuticals, Inc. in Q3 2017 and held it in 5 quarters.
  • PDT Partners's Concert Pharmaceuticals, Inc. position peaked at $3.72M in Q4 2017.
  • 79 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2021.

Based on PDT Partners's 13F filing for Q2 2021, filed 16 Aug 2021.